|
|
|
|
|
by reasonattlm
2358 days ago
|
|
I can't say as I like his take on the longevity industry. It is the take that will produce few meaningful advances, the "looking under the lamp because that's where the light is" way of approaching life. Just more marginally better drugs that do a little bit more than those of 10 years ago. Sadly investors probably care very little from a financial position as to whether a drug works or not, as their exit usually happens somewhere between trials at Phase 1 and Phase 2. Earlier in the longevity market because it is hot. I've put together Request for Startup lists for the longevity industry for the past few years, based on fairly detailed insight into the state of the science. https://www.fightaging.org/archives/2019/02/request-for-star... https://www.fightaging.org/archives/2017/12/request-for-star... https://www.fightaging.org/archives/2016/12/request-for-star... Because things move slowly in biotech, just about everything in these documents except for more senolytics is still valid. |
|
As you are as familiar as few people are with the topic, I'd like to ask you for some advice, if possible: What do you think is the best way for someone like me (currently biochem undergrad, with ~7 years broad software engineering experience), to have an impact in the field?